IP Library Granted Patent US 8,258,095
Granted Patent B2
US 8,258,095 · App. 12/539,499 · Granted Sep 4, 2012

Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,258,095
App. No.
12/539,499
Granted
Sep 4, 2012
Kind
B2
Abstract

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Claims (11)

1. A method of controlling glycemia related to one or more daily meals in an individual with diabetes without adjusting an insulin dose for meal content comprising the step of administering a standard dosage of an ultrarapid acting insulin formulation at a mealtime for one or more of the daily meals, wherein, for any given daily meal, the standard dosage for the daily meal has been predetermined based on said individual's usual meal content for the daily meal, and wherein, at least occasionally, content of the daily meal varies from ≧25% to ≦250% of the individual's usual meal content, and the standard dosage is not adjusted when a meal is consumed that varies from ≧25% to ≦250% of the individual's usual meal content as used in the determination of the standard dosage.

2. The method of claim 1 wherein the ultrarapid-acting insulin formulation is insulin-FDKP.

3. The method of claim 1 wherein a standard dosage is administered at each mealtime.

4. The method of claim 1 wherein a single predetermined dosage is used for each mealtime.

5. The method of claim 1 wherein a predetermined dosage is set for each mealtime.

6. The method of claim 1 wherein meal content is assessed as glycemic load.

7. The method of claim 1 wherein meal content is assessed as caloric content.

8. The method of claim 1 wherein meal content is ≧25% of a usual meal content as used in predetermination of the standard dose.

9. The method of claim 8 wherein meal content is ≧50% of a usual meal content as used in predetermination of the standard dose.

10. The method of claim 1 wherein meal content is ≦200% of a usual meal content as used in predetermination of the standard dose.

11. The method of claim 10 wherein meal content is ≦150% of a usual meal content as used in predetermination of the standard dose.

Assignments (8)
PATENT SECURITY AGREEMENT Recorded Aug 12, 2025
From: MANNKIND CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 072444/0525 →
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →
SECURITY INTEREST Recorded Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2016
From: AVENTISUB LLC
To: MANNKIND CORPORATION
Reel/Frame 040588/0008 →
PATENT SECURITY AGREEMENT Recorded Sep 26, 2014
From: MANNKIND CORPORATION
To: AVENTISUB LLC
Reel/Frame 033831/0110 →
SECURITY AGREEMENT Recorded Jul 3, 2013
From: MANNKIND CORPORATION
To: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
Reel/Frame 030740/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2009
From: BOSS, ANDERS HASAGER; PETRUCCI, RICHARD; HOWARD, CAMPBELL; MANN, ALFRED
To: MANNKIND CORPORATION
Reel/Frame 023444/0243 →